Zobrazeno 1 - 10
of 16
pro vyhledávání: '"Masaru KAWASHIMA"'
Publikováno v:
Journal of Diabetes Investigation, Vol 11, Iss 3, Pp 640-646 (2020)
Abstract Aims/Introduction To explore the factors associated with the glucose‐lowering efficacy of sitagliptin treatment in Japanese patients with type 2 diabetes mellitus. Materials and Methods This was a post‐hoc analysis of pooled data from se
Externí odkaz:
https://doaj.org/article/9b148ff1c584488ebaba2e0c17fb168f
Autor:
Tomoya Mita, Naoto Katakami, Mitsuyoshi Takahara, Masaru Kawashima, Fumitaka Wada, Hiroki Akiyama, Naru Morita, Yoko Kidani, Toshitaka Yajima, Iichiro Shimomura, Hirotaka Watada
Publikováno v:
The Journal of Clinical Endocrinology & Metabolism. 107:2424-2432
Context J-DISCOVER is a prospective observational cohort study aiming to understand the current management of patients with early-stage type 2 diabetes mellitus (T2DM) in Japan, enrolling patients initiating second-line treatment. Objective The curre
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2588142ae91dbc3d7876f77664a6adbf
https://doi.org/10.1210/clinem/dgac420
https://doi.org/10.1210/clinem/dgac420
Publikováno v:
Journal of Architecture and Planning (Transactions of AIJ). 87:172-183
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f2462f6b2ad8aa637760d083a551dad9
https://doi.org/10.3130/aija.87.172
https://doi.org/10.3130/aija.87.172
Publikováno v:
Journal of Diabetes Investigation, Vol 11, Iss 3, Pp 640-646 (2020)
Journal of Diabetes Investigation
Journal of Diabetes Investigation
Aims/Introduction To explore the factors associated with the glucose‐lowering efficacy of sitagliptin treatment in Japanese patients with type 2 diabetes mellitus. Materials and Methods This was a post‐hoc analysis of pooled data from seven sitag
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e929c7f7bfa12f16194229f8101e76b9
https://doaj.org/article/9b148ff1c584488ebaba2e0c17fb168f
https://doaj.org/article/9b148ff1c584488ebaba2e0c17fb168f
Autor:
Hideaki Suna, Kentaro Machida, Masaru Kawashima, Yoshinori Ashihara, Hiroshi Koto, Hiromasa Inoue, Makoto Yoshida, Tohru Tsuda, Masakazu Ichinose, Shohei Takata, Masaharu Kinoshita, Tomotaka Kawayama
Publikováno v:
International Journal of Chronic Obstructive Pulmonary Disease
Kentaro Machida,1,* Tomotaka Kawayama,2,* Masaharu Kinoshita,3,* Masakazu Ichinose,4 Tohru Tsuda,5 Shohei Takata,6 Hiroshi Koto,7 Makoto Yoshida,8 Yoshinori Ashihara,9 Masaru Kawashima,10 Hideaki Suna,10 Hiromasa Inoue1 1Department of Pulmonary Medic
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4e4e003eb49a6d36163e3dd9b4ac23a4
https://doi.org/10.2147/copd.s223002
https://doi.org/10.2147/copd.s223002
Autor:
Masaru Kawashima, Iichiro Shimomura, Fumitaka Wada, Naoto Katakami, Tomoya Mita, Toshitaka Yajima, Mitsuyoshi Takahara, Hirotaka Watada
Publikováno v:
Diabetes Therapy
Introduction J-DISCOVER aims to research the treatment reality of Japanese patients with type 2 diabetes mellitus who begin second-line treatment. Here we report baseline characteristics and factors associated with selection of second-line treatment.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::049b91687e9e4764e272909cd24b51eb
https://pubmed.ncbi.nlm.nih.gov/32504219
https://pubmed.ncbi.nlm.nih.gov/32504219
Publikováno v:
Journal of Architecture and Planning (Transactions of AIJ). 83:121-128
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b9280791543391385bfc335fa97c7c73
https://doi.org/10.3130/aija.83.121
https://doi.org/10.3130/aija.83.121
Autor:
Hirotaka Watada, Naoto Katakami, Mitsuyoshi Takahara, Kiyoshi Hashigami, Masaru Kawashima, Iichiro Shimomura, Tomoya Mita
Publikováno v:
Diabetes Therapy
Introduction It is estimated that 642 million adults worldwide will have diabetes by 2040, with 80–90% of these having type 2 diabetes mellitus (T2DM). While many new antidiabetic agents have been introduced in recent years, approximately 40% of T2
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0745c629d70866007540e20b7e01b9ea
http://europepmc.org/articles/PMC5801237
http://europepmc.org/articles/PMC5801237
Publikováno v:
Journal of Architecture and Planning (Transactions of AIJ). 81:751-758
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8454410c97ed66712f54236e1a7508a7
https://doi.org/10.3130/aija.81.751
https://doi.org/10.3130/aija.81.751
Autor:
Masaru Kawashima, Daisuke Yanagida, Juan Camilo Arjona Ferreira, Taro Okamoto, Toshiomi Minamide, Masato Odawara, Naoko Tajima, Takashi Kadowaki
Publikováno v:
Diabetology International. 4:160-172
This multicenter, randomized study assessed the efficacy and safety of the dipeptidyl peptidase 4 inhibitor sitagliptin added to insulin monotherapy in Japanese patients with type 2 diabetes mellitus (T2DM). This study had an initial 16-week, double-
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0f7688242b87c140aaf511da374e4534
https://doi.org/10.1007/s13340-013-0109-z
https://doi.org/10.1007/s13340-013-0109-z